Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

Exclusion Criteria

• •1. History of prior major abdominal surgery as judged by the investigator
• •2. Pre-existing lung disease that could impact participant safety in the opinion of the investigator
• •3. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton- Lambert syndrome, or amyotrophic lateral Sclerosis)
• •4. At high risk of deep vein thrombosis as judged by the investigators determined by a Caprini score of 3 or higher
• •5. Slow vital capacity that is below 80% of normal value for respective race, age, height, and gender or below 2.5 Liters (L) of absolute volume
• •6. Pulse oximetry below 95%
• •7. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of ≥ 32
• •8. Reported use of any botulinum toxin within 3 months prior to the date of surgery
• •9. Use of long acting opioids within 3 days or any opioid medication within 24 hours prior to surgery
• •10. Aminoglycoside intake within 48 hours prior to or during surgery
• •11. Participants on anti-depressant or anti-psychotic medications
• •12. Reported pain score of 2 or more at screening on the 11-point scale numerical pain rating scale-administered after an activity (NPRS-A) following an activity after and walking approximately 10 feet.